"Despite the availability of biosimilar somatropin plus epoetin alfa and zeta in Europe, surveyed European endocrinologists and nephrologists remain less familiar with biosimilars compared with their oncologist colleagues, although we do see marked differences by country among surveyed nephrologists," said BioTrends Research Group Senior Director, Andrew Merron, Ph.D. "Conversely, reflecting the good acceptance of biosimilars and the relatively high level of biosimilar filgrastim uptake, surveyed European hematologist-oncologists and medical oncologists report a high level of familiarity with biosimilars. We expect this finding will contribute to a comparatively rapid uptake of complex biosimilars among oncologists compared with other specialists."
The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at
|SOURCE BioTrends Research Group|
Copyright©2012 PR Newswire.
All rights reserved